{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:51:43Z","timestamp":1792741903130,"version":"4.5.0"},"reference-count":25,"publisher":"Medical Association of Nippon Medical School","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2023,4,25]]},"DOI":"10.1272\/jnms.jnms.2023_90-215","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T22:12:24Z","timestamp":1676931144000},"page":"149-156","source":"Crossref","is-referenced-by-count":8,"title":["Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review"],"prefix":"10.1272","volume":"90","author":[{"given":"Izumi","family":"Fukuda","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Ntali G, Kassi E, Alevizaki M. Endocrine sequelae of immune checkpoint inhibitors. Hormones (Athens). 2017 Oct;16 (4):341-50. doi: 10.14310\/horm.2002.1754","DOI":"10.14310\/horm.2002.1754"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017 Apr;13 (4):195-207. doi: 10.1038\/nrendo.2016.205","DOI":"10.1038\/nrendo.2016.205"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Rev Endocrinol Metab. 2019 Nov;14 (6):381-98. doi: 10.1080\/17446651.2019.1701434","DOI":"10.1080\/17446651.2019.1701434"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am J Pathol. 2016 Dec;186 (12):3225-35. doi: 10.1016\/j.ajpath.2016.08.020","DOI":"10.1016\/j.ajpath.2016.08.020"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014 Apr 2;6 (230):230ra45. doi: 10.1126\/scitranslmed.3008002","DOI":"10.1126\/scitranslmed.3008002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003 Jul 8;100 (14):8372-7. doi: 10.1073\/pnas.1533209100. Epub 2003 Jun 25","DOI":"10.1073\/pnas.1533209100"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Paschou SA, Stefanaki K, Psaltopoulou T, et al. How we treat endocrine complications of immune checkpoint inhibitors. ESMO Open. 2021 Feb;6 (1):100011. doi: 10.1016\/j.esmoop.2020.100011","DOI":"10.1016\/j.esmoop.2020.100011"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Sznol M, Postow MA, Davies MJ, et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017 Jul;58:70-6. doi: 10.1016\/j.ctrv.2017.06.002","DOI":"10.1016\/j.ctrv.2017.06.002"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006 Jul-Aug;29 (4):455-63. doi: 10.1097\/01.cji.0000208259.73167.58","DOI":"10.1097\/01.cji.0000208259.73167.58"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer. 2018 Mar 15;124 (6):1111-21. doi: 10.1002\/cncr.31200","DOI":"10.1002\/cncr.31200"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Mahzari M, Liu D, Arnaout A, Lochnan H. Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes. 2015;8:21-8. doi: 10.4137\/CMED.S22469","DOI":"10.4137\/CMED.S22469"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Stelmachowska-Bana\u015b M, Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect. 2020 Oct;9 (10):R207-28. doi: 10.1530\/EC-20-0342","DOI":"10.1530\/EC-20-0342"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015 Feb 15;21 (4):749-55. doi: 10.1158\/1078-0432.CCR-14-2353","DOI":"10.1158\/1078-0432.CCR-14-2353"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018 Sep 15;124 (18):3706-14. doi: 10.1002\/cncr.31629","DOI":"10.1002\/cncr.31629"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Albarel F, Castinetti F, Brue T. Management of endocrine disease: Immune check point inhibitors-induced hypophysitis. Eur J Endocrinol. 2019 Sep 1;181 (3):R107-18. doi: 10.1530\/EJE-19-0169","DOI":"10.1530\/EJE-19-0169"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014 Nov;99 (11):4078-85. doi: 10.1210\/jc.2014-2306","DOI":"10.1210\/jc.2014-2306"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Kobayashi T, Iwama S, Yasuda Y, et al. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer. 2020 Jul;8 (2):e000779. doi: 10.1136\/jitc-2020-000779","DOI":"10.1136\/jitc-2020-000779"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021 Jul;17 (7):389-99. doi: 10.1038\/s41574-021-00484-3","DOI":"10.1038\/s41574-021-00484-3"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Lupi I, Brancatella A, Cosottini M, et al. Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases. Endocrinol Diabetes Metab Case Rep. 2019 Oct 12;2019:19-0102. doi: 10.1530\/EDM-19-0102","DOI":"10.1530\/EDM-19-0102"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Cho KY, Miyoshi H, Nakamura A, Kurita T, Atsumi T. Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [Letter to the Editor]. Endocr J. 2017 Feb 27;64 (2):235-6. doi: 10.1507\/endocrj.EJ16-0596","DOI":"10.1507\/endocrj.EJ16-0596"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Ono M, Fukuda I, Nagao M, et al. HLA analysis of immune checkpoint inhibitor-induced and idiopathic isolated ACTH deficiency. Pituitary. 2022 Aug;25 (4):615-21. doi: 10.1007\/s11102-022-01231-1","DOI":"10.1007\/s11102-022-01231-1"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Joshi MN, Whitelaw BC, Carroll PV. Mechanisms in endocrinology: Hypophysitis: diagnosis and treatment. Eur J Endocrinol. 2018 Sep;179 (3):R151-63. doi: 10.1530\/EJE-17-0009","DOI":"10.1530\/EJE-17-0009"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Kanie K, Iguchi G, Bando H, et al. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome. Cancer Immunol Immunother. 2021 Dec;70 (12):3669-77. doi: 10.1007\/s00262-021-02955-y","DOI":"10.1007\/s00262-021-02955-y"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Feb 1;4 (2):173-82. doi: 10.1001\/jamaoncol.2017.3064","DOI":"10.1001\/jamaoncol.2017.3064"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Takahashi Y. Mechanisms in endocrinology: Autoimmune hypopituitarism: novel mechanistic insights. Eur J Endocrinol. 2020 Apr;182 (4):R59-66. doi: 10.1530\/EJE-19-1051","DOI":"10.1530\/EJE-19-1051"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/2\/90_JNMS.2023_90-215\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T04:07:58Z","timestamp":1685765278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/2\/90_JNMS.2023_90-215\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2023_90-215","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"article-number":"JNMS.2023_90-215"}}